News, literature and expert perspectives on PCSK9 inhibition
ACC 2018 A prespecified FOURIER-analysis showed that evolocumab decreases CV events across hsCRP strata, with greater absolute risk reductions in patients with higher baseline hsCRP.
ACC 2018 Dr. Valentin Fuster explains why he thinks that the results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.
ACC 2018 Prof. Gabriel Steg discusses the 15% reduction of MACE obtained with alirocumab, with a good safety profile. The observed CV benefit was greater in patients who had a higher LDL-c at baseline.
ACC 2018 Treatment with alirocumab on top of high-intensity statins lowered MACE by 15% in patients with recent ACS in the ODYSSEY OUTCOMES trial and was associated with a lower rate of all-cause death.
A preclinical study shows that DS-9001a interferes with PCSK9 binding to the LDL receptor and PCSK9-mediated LDLR degradation, and lowers LDL-c, and it is produced in a microbial production system.
In a sub-analysis of the ILLUMINATE study, PCSK9 and Lp(a) levels were dose-dependently increased by atorvastatin in patients at high CV risk.
In type 2 diabetic patients with mixed dyslipidemia on maximal statin therapy, the addition of the PCSK9 inhibitor alirocumab is more effective than usual care.
//PCSK9// genetic variants, that produce lower levels of LDL-c, are not associated with the risk of ischemic stroke, in contrast to significant association with the risk of CHD.
Evolocumab significantly changes lipoprotein particle number and size, irrespective of concordance with LDL-c at baseline or disease status.
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.
Dr. Robert Giugliano summarizes what we have learned over the past decades about the effectiveness and safety of reducing LDL-c to very low values.
//Ex vivo// LDL-receptor expression is inversely associated with the plasma levels of LDL-c and apoB in HoFH patients before and after treatment with evolocumab.